Literature DB >> 1370958

Tenascin expression in human glioma cell lines and normal tissues.

J B Ventimiglia1, C J Wikstrand, L E Ostrowski, M A Bourdon, V A Lightner, D D Bigner.   

Abstract

Tenascin expression was evaluated in 21 human glioma cell lines and in normal adult tissue extracts by Western and Northern blotting. The cell lines differed in their relative expression of tenascin in the cell-associated and supernatant compartments. Glioma cell line tenascin production was not uniformly stimulated by changes in fetal bovine serum concentration in the growth media. In most glioma cell lines and normal tissue extracts, reducing Western blots and Northern blots revealed two tenascin species, respectively: a major 340 kDa polypeptide and a 9 kb RNA transcript accompanied by a less intense 250 kDa polypeptide and 7 kDa RNA species. In U-87 MG and in normal adult kidney extracts, however, the 250 kDa band and 7 kb transcript were more prominent. Quantitation of tenascin in the glioma lines revealed variable levels that were significantly higher than those in the tissue extracts.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370958     DOI: 10.1016/0165-5728(92)90029-k

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

1.  The distribution of extracellular matrix proteins and CD44S expression in human astrocytomas.

Authors:  B Oz; F A Karayel; N L Gazio; F Ozlen; K Balci
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 2.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

3.  Tenascin distribution in human brain tumours.

Authors:  P Castellani; A Dorcaratto; A Siri; L Zardi; G L Viale
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

4.  Distribution pattern of tenascin-C in glioblastoma: correlation with angiogenesis and tumor cell proliferation.

Authors:  Senija Behrem; Kamelija Zarković; Neven Eskinja; Nives Jonjić
Journal:  Pathol Oncol Res       Date:  2005-12-31       Impact factor: 3.201

5.  Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages.

Authors:  Anna M Piccinini; Lorena Zuliani-Alvarez; Jenny M P Lim; Kim S Midwood
Journal:  Sci Signal       Date:  2016-08-30       Impact factor: 8.192

6.  A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

Authors:  David A Reardon; Michael R Zalutsky; Gamal Akabani; R Edward Coleman; Allan H Friedman; James E Herndon; Roger E McLendon; Charles N Pegram; Jennifer A Quinn; Jeremy N Rich; James J Vredenburgh; Annick Desjardins; Sridharan Guruangan; Susan Boulton; Renee H Raynor; Jeanette M Dowell; Terence Z Wong; Xiao-Guang Zhao; Henry S Friedman; Darell D Bigner
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

7.  Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.

Authors:  Roger E McLendon; Gamal Akabani; Henry S Friedman; David A Reardon; Linda Cleveland; Ilkcan Cokgor; James E Herndon; Carol Wikstrand; Susan T Boulton; Allan H Friedman; Darell D Bigner; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2007-03-30       Impact factor: 2.408

8.  Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.

Authors:  D D Bigner; M Brown; R E Coleman; A H Friedman; H S Friedman; R E McLendon; S H Bigner; X G Zhao; C J Wikstrand; C N Pegram
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 9.  Targeted therapies for malignant glioma: progress and potential.

Authors:  Ronald W Mercer; Matthew A Tyler; Ilya V Ulasov; Maciej S Lesniak
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

10.  Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds.

Authors:  Jan Pilch; Darren M Brown; Masanobu Komatsu; Tero A H Järvinen; Meng Yang; David Peters; Robert M Hoffman; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.